US-based CytImmune gears up to target cancer cure

We all know there is no magic bullet for cancer . But scientists across the world are working on novel projects like cancer vaccines and newer tools like nanotechnology to conquer cancer, reports CNBC-TV18.
 
CytImmune is a small US-based nanotechnology company , but it has set a big goal for itself. CytImmune scientists are developing a nanotechnology-based Drug Delivery System that can target cancerous tumours leaving healthy organs and tissues untouched.

Dr Larry Tamarkin , CEO , Cytimmune, says, “These particles are especially designed with our proprietary technology.”
 
If all goes well in the human trials, CytImmune could provide leads to more precision-based cancer therapies. This is because most experts feel the biggest drawback of most anti-cancer drugs is that they tend to damage healthy tissues. These drugs may not really be targetted therapies as suggested by companies.

Several drug makers like Novartis , Merck and Genentech are also working on a few therapeutic vaccines that can induce the patients’ own immune system to act on the deadly cancer cells.

Elmar Schenny , CEO , Merck Germany , says, “It is in phase III and help attack tumours.”

With the help of genomics and proteomics, experts say over the next few years, it will be easier to see a real headway in predicting and curing cancer.